Yes, I listened to it again today. It sounded like they had prepared some type of data that was submitted to the FDA to explain their plans going forward. Whether that submission might be enough to satisfy the FDA or if the FDA will require further testing/info, who knows.
Or, maybe they already have feedback from the FDA and just need to develop a plan to meet the "new" FDA requirements (or throw in the towel). The trouble with this CC is that it was recorded before the Sep. 9 Type A meeting and he didn't have any feedback to report. I guess we just have to wait now because it sounded like Jay wasn't going to provide any further updates until they hear back from the FDA minutes which could be 30 days.
From FDA info:
Type A Meeting – is a meeting that is "immediately necessary for an otherwise stalled drug development program to proceed." This type of meeting refers to meetings to resolve disputes, talk about clinical holds, special protocols. Think of them as a "Type A Personality" meetings. They should be scheduled within 30 days of the time that FDA gets a written request for a meeting.